Laurus Labs gets USFDA endorsements for ANDAs TLE 400 and TLE 600 tablets

Overview

• Post By : Kumar Jeetendra


• Source: Agencies


• Date: 19 May,2020

Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010) Laurus Labs Ltd is satisfied to declare that the Company has gotten an endorsement from USFDA under PEPFAR (President’s Emergency Plan for AIDS Relief) for two ANDAs (Abbreviated New Drug Application) TLE 400 (Tenofovir/Lamivudine/Efavirenz – 300/300/400mg) and TLE 600 (Tenofovir/Lamivudine/Efavirenz – 300/300/600mg) tablets.

Laurus Labs is one of only a handful barely any players in the ARV section to get an endorsement for TLE 400 tablets. TLE 400 is one of the most favored regimens in the ARV first line treatment. The Company previously got WHO Pre-Qualification for TLE 400 (Tenofovir/Lamivudine/Efavirenz – 300/300/400mg)

These endorsements empowers Laurus Labs to dispatch both the items in a few LMIC markets.

Portions of Laurus Labs Ltd was last exchanging BSE at Rs.442.25 when contrasted with the past close of Rs. 425.75. The complete number of offers exchanged during the day was 78672 in more than 3695 exchanges.

The stock hit an intraday high of Rs. 457 and intraday low of 430.5. The net turnover during the day was Rs. 35169378.